Celentyx Signs Drug Reprofiling Agreement With Meiji Seika Kaisha

Celentyx has entered into a drug reprofiling agreement with Meiji Seika Kaisha to seek alternative development paths for Meiji drug candidates, using an application of the Immuno-Profiling platform – Novel Clinical Indication Profiling (NCIP).

Celentyx’s NCIP identifies new uses for safe drugs to treat human immune system diseases e.g. inflammation, haematological cancers (leukaemias and lymphomas), allergy, autoimmune disease and graft rejection.

Nicholas Barnes, CEO of Celentyx, said: We are particularly pleased to add Meiji as a partner since they have a number of candidate drugs impacting a target that we have identified on key cell subsets within the human immune system. Celentyx’s NCIP provides an evaluation of a drug’s ability to signal responses in human immune cells with resolution to determine the therapeutic potential of small molecules and biologicals. Our goal is to provide partners with substantial value and revive development paths for drugs that retain potential for immune system disorders.